Specialized contractile cells that differentiate from fibroblasts during wound healing, characterized by expression of alpha-smooth muscle actin (α-SMA) and formation of stress fibres. They are responsible for generating mechanical tension to close wounds (producing forces of 20-100 nanoNewtons per cell) and depositing extracellular matrix proteins. Under normal conditions, myofibroblasts undergo apoptosis once wound closure is complete; their persistence drives pathological fibrosis.
Think of myofibroblasts as emergency construction crews with grappling hooks. When a building (tissue) is damaged, regular construction workers (fibroblasts) get an urgent call from the city (TGF-β1 and mechanical stress signals). They rush to the site, put on specialized equipment — heavy-duty harnesses with ropes (α-SMA stress fibres) — and transform into emergency crews (myofibroblasts).
These crews anchor themselves to both sides of a collapsed structure and literally pull the broken edges together with their ropes, while simultaneously pouring concrete (collagen I and III) to fill the gaps. The tension they generate is critical — without it, the wound stays open. But here's where things can go wrong: in a normal repair, once the building is stable, these emergency crews are supposed to dismantle their equipment and go home (undergo apoptosis).
However, if the "all clear" signal never arrives — because chronic inflammation keeps ringing the alarm, or because specialized pro-resolving mediators (SPMs) aren't present to call them off — the crews never leave. They keep pulling and pouring concrete indefinitely, turning flexible tissue into rigid scar tissue. The building becomes stiff, immobile, and dysfunctional. This is fibrosis: emergency workers who forgot how to stop working.
Myofibroblast differentiation and function involves multiple converging pathways:
Mechanical tension + TGF-β1 signaling → myofibroblast differentiation
- Tissue injury → release of TGF-β (primarily TGF-β1) from macrophages, damaged extracellular matrix, and activated platelets
- TGF-β1 binds TGF-β receptor II (TβRII) → recruits and phosphorylates TβRI (ALK5)
- TβRI phosphorylates SMAD2/3 → SMAD2/3 binds SMAD4 → nuclear translocation
- SMAD complex binds DNA at SMAD-binding elements (SBEs) → transcription of:
- α-SMA incorporates into stress fibres → contractile apparatus forms
- Mechanical tension is critical: fibroblasts on stiff ECM (>5 kPa) preferentially differentiate; soft ECM (<1 kPa) prevents myofibroblast formation
- Integrin signaling (particularly α5β1 and αvβ3) senses mechanical stiffness → activates focal adhesion kinase (FAK) → enhances TGF-β signaling via RhoA/ROCK pathway
α-SMA + myosin II + actin → stress fibres that generate contractile force:
- Myofibroblasts express ED-A fibronectin splice variant, which stabilizes focal adhesions
- RhoA-ROCK pathway phosphorylates myosin light chain → increases contractility
- Forces transmitted through integrin-ECM connections → wound edge approximation
Activated myofibroblasts are ECM factories:
- Produce 3-5× more collagen I than resting fibroblasts
- Secrete collagen III, fibronectin, periostin, tenascin-C
- Express lysyl oxidase (LOX) → cross-links collagen → increases tensile strength
- Produce matrix metalloproteinase inhibitors (TIMPs) → reduces ECM degradation
Normal resolution pathway:
- Wound closure achieved → mechanical tension decreases
- specialized pro-resolving mediators (SPMs) — particularly RvD1, MaR1, RvE1 — activate apoptotic pathways in myofibroblasts
- SPMs bind ALX-FPR2 and other receptors → activate caspase cascade
- Myofibroblast apoptosis → phagocytosis by M2 macrophages
- ECM remodeling begins → tissue normalizes
Pathological persistence (fibrosis):
- chronic inflammation → sustained TGF-β1 production
- Inadequate SPM synthesis (due to omega-3 deficiency, chronic stress, or impaired resolution machinery)
- Sustained mechanical stiffness → positive feedback loop (stiff ECM → more myofibroblasts → stiffer ECM)
- Chronic hypoxia → sustained HIF-1 activation → pro-fibrotic gene expression
- Myofibroblasts fail to undergo apoptosis → fibrotic disease
graph TD
A[Tissue Injury] --> B["TGF-β1 Release"]
A --> C[Mechanical Tension]
B --> D["TβRII/TβRI Activation"]
D --> E[SMAD2/3 Phosphorylation]
E --> F[SMAD2/3/4 Complex]
F --> G[Nuclear Translocation]
G --> H["α-SMA Expression"]
G --> I[Collagen I/III Production]
C --> J[Integrin-FAK Signaling]
J --> K[RhoA/ROCK Activation]
K --> H
H --> L[Stress Fibre Formation]
L --> M[Contractile Force Generation]
M --> N[Wound Closure]
N --> O{Resolution Signals?}
O -->|SPMs Present| P[Myofibroblast Apoptosis]
O -->|SPMs Absent| Q[Chronic Inflammation]
Q --> R[Persistent Myofibroblasts]
R --> S[Fibrosis]
P --> T[Tissue Remodeling]
T --> U[Normal Tissue]
Myofibroblasts can arise from multiple sources:
- Resident fibroblasts (primary source, ~50-70%)
- Pericytes (particularly in kidney and liver fibrosis)
- Epithelial-to-mesenchymal transition (EMT) (10-30% in some organs)
- Endothelial-to-mesenchymal transition (EndMT)
- Bone marrow-derived fibrocytes (circulating progenitors)
Myofibroblast biology is central to understanding the balance between healing and pathology. In cPNI, this maps directly to:
Metamodel 5 (Resolution): The failure of myofibroblast apoptosis represents a breakdown in inflammatory resolution. Patients with chronic wounds, fibrotic conditions, or tissue stiffness have inadequate resolution signaling — often due to omega-3 deficiency, chronic cortisol elevation impairing SPM synthesis, or persistent psychological stress maintaining inflammatory tone.
Selfish Immune System: Myofibroblasts persist when the immune system fails to transition from repair to resolution mode. The "selfish" priority of preventing infection (via wound closure) overrides the long-term health cost of fibrosis.
Evolutionary Mismatch: Our ancestors rarely lived long enough to develop extensive fibrosis. Modern longevity, combined with chronic inflammatory states (from sedentary behavior, processed foods, chronic stress), means myofibroblasts persist in contexts they were never "designed" for.
Beneficial myofibroblast activity (acute wound healing):
- Surgical wounds (myofibroblasts appear day 5-7, peak day 14-21)
- Traumatic injuries requiring wound contraction
- Intervention goal: Support appropriate activation without excess (ensure adequate protein intake 1.6-2.2 g/kg, vitamin C 1-2 g/day for collagen synthesis, zinc 30-50 mg/day for wound healing)
Pathological myofibroblast persistence (fibrosis):
- Idiopathic pulmonary fibrosis: Lung stiffness, reduced compliance, FVC <80% predicted
- Liver cirrhosis: Hepatic stellate cells → myofibroblasts
- Chronic kidney disease: Tubulointerstitial fibrosis, eGFR decline
- Frozen shoulder: Capsular fibrosis with myofibroblast infiltration
- Systemic sclerosis (scleroderma): Skin and organ fibrosis
- Crohn's disease strictures: Intestinal myofibroblast accumulation
- Post-radiation fibrosis
- Keloid and hypertrophic scar formation
¶ Clinical Thresholds and Biomarkers
- α-SMA immunostaining: Diagnostic marker in tissue biopsies (>30% α-SMA+ cells suggests active fibrosis)
- Procollagen type I C-peptide (PICP): Serum marker of collagen synthesis (>100 μg/L suggests active fibrosis)
- Matrix metalloproteinase-7 (MMP-7): Elevated in pulmonary fibrosis (>4 ng/mL)
- Tissue stiffness: Measured via ultrasound elastography or shear wave elastography (>15 kPa in liver suggests cirrhosis)
- TGF-β1 levels: Plasma levels >40 ng/mL associated with fibrotic progression
Prevent excessive myofibroblast activation:
- Omega-3 supplementation: EPA+DHA 2-4 g/day to support SPM synthesis
- Polyphenols: Curcumin (1-2 g/day), resveratrol (500-1000 mg/day), EGCG (400-800 mg/day) inhibit TGF-β/SMAD signaling
- Reduce mechanical tension: Early mobilization protocols in wound healing; manual therapy for fascial restrictions
- Address chronic hypoxia: Improve tissue oxygenation (exercise, breathing exercises, altitude training)
- Anti-fibrotic nutrients: NAC (1200-1800 mg/day) as glutathione precursor; vitamin E (400-800 IU/day)
- Vagal tone optimization: Myofibroblast apoptosis enhanced by parasympathetic signaling via cholinergic anti-inflammatory pathway
Support appropriate resolution:
- SPM supplementation: Specialized pro-resolving mediator concentrates (e.g., SPM Active containing RvE1, RvD1, MaR1)
- Psychological interventions: Chronic stress impairs resolution; EMDR, somatic experiencing, or mindfulness reduce cortisol and support SPM synthesis
- Circadian optimization: TGF-β1 shows circadian variation; sleep deprivation increases fibrotic signaling
Clinical decision-making:
- In acute wounds (<4 weeks): Support myofibroblast function with nutrients for collagen synthesis
- In chronic wounds (>12 weeks) or fibrotic conditions: Shift focus to resolution and apoptosis promotion
- In movement disorders with fascial restrictions: Consider myofibroblast-mediated stiffness; manual therapy + SPMs + load management
- Myofibroblasts express α-SMA (alpha-smooth muscle actin), distinguishing them from regular fibroblasts
- Generate contractile forces of 20-100 nanoNewtons per cell, sufficient to close wounds spanning several centimeters
- Appear 5-7 days post-injury, peak at 14-21 days, and should undergo apoptosis by 4-6 weeks in normal healing
- Produce 3-5× more collagen I than resting fibroblasts, primarily types I and III
- Require both TGF-β1 signaling AND mechanical tension (ECM stiffness >5 kPa) for stable differentiation
- Express ED-A fibronectin splice variant, which is absent in normal tissue and serves as a fibrosis biomarker
- In fibrotic diseases, myofibroblasts can persist for years or decades, continuously depositing ECM
- SPMs (resolvins, maresins, protectins) promote myofibroblast apoptosis via caspase-3 activation and Bcl-2 downregulation
- Chronic hypoxia and sustained HIF-1α activation drive myofibroblast persistence through increased TGF-β, CCN2/CTGF, and angiotensin II
- Approximately 50-70% of myofibroblasts arise from resident fibroblasts; 10-30% from epithelial-to-mesenchymal transition in some organs
- Myofibroblast-mediated wound contraction reduces wound surface area by up to 80% in large open wounds
- Pharmacological targeting with pirfenidone (anti-fibrotic) or nintedanib (tyrosine kinase inhibitor) reduces myofibroblast activity in idiopathic pulmonary fibrosis
- fibroblasts — precursor cells that differentiate into myofibroblasts under TGF-β1 and mechanical tension
- TGF-β — primary cytokine driving myofibroblast differentiation via SMAD2/3 signaling pathway
- wound healing — myofibroblasts are essential during proliferative phase for wound contraction and matrix deposition
- specialized pro-resolving mediators — SPMs (RvD1, MaR1, RvE1) promote myofibroblast apoptosis and prevent fibrosis
- fibrosis — pathological persistence of myofibroblasts leads to excessive ECM deposition and organ dysfunction
- extracellular matrix — myofibroblasts are primary producers of collagen I, collagen III, and fibronectin during repair
- macrophages — M2 macrophages secrete TGF-β1 that activates myofibroblasts; also clear apoptotic myofibroblasts during resolution
- collagen — myofibroblasts synthesize large quantities of collagen I and III for tissue repair and scarring
- chronic inflammation — sustained inflammatory signaling prevents myofibroblast apoptosis, leading to fibrotic disease
- HIF-1 — chronic hypoxia and HIF-1α activation promote pro-fibrotic gene expression in myofibroblasts
- resolution — inadequate resolution signaling (low SPMs) is central to myofibroblast persistence and fibrosis
- frozen shoulder — capsular fibrosis driven by myofibroblast accumulation and contracture
- IL-6 — pro-inflammatory cytokine that can enhance TGF-β signaling and myofibroblast differentiation
- RhoA — small GTPase that activates ROCK pathway, increasing myosin contractility in myofibroblasts
- integrin — αvβ3 and α5β1 integrins mediate mechanotransduction, sensing ECM stiffness and promoting myofibroblast activation
- IL-10 — anti-inflammatory cytokine that can suppress TGF-β signaling and reduce myofibroblast differentiation
- omega-3 fatty acids — EPA and DHA are substrates for SPM synthesis; deficiency impairs myofibroblast resolution
- Crohn's disease — intestinal strictures result from myofibroblast-mediated fibrosis in chronic inflammation
- cortisol — chronic elevation impairs SPM synthesis enzymes (15-LOX, 5-LOX), preventing myofibroblast apoptosis
- curcumin — polyphenol that inhibits TGF-β/SMAD signaling and reduces myofibroblast activation in experimental models
- idiopathic pulmonary fibrosis — progressive lung disease characterized by excessive myofibroblast activity and collagen deposition
- vagus nerve — cholinergic anti-inflammatory pathway modulates myofibroblast activity; vagal stimulation may enhance resolution
- lysyl oxidase — enzyme produced by myofibroblasts that cross-links collagen, increasing ECM tensile strength and stiffness